Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
Prespecified secondary analysis of the STEP-HFpEF Program testing whether semaglutide 2.4 mg benefits in obesity-related HFpEF differ by atrial fibrillation history. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found that once-weekly semaglutide 2.4 mg attenuated left atrial and right ventricular remodelling versus placebo, without changing left ventricular systolic function. PICO summary and expert commentary.
How patient and public involvement shaped the design of ASCEND PLUS, a decentralised RCT of oral semaglutide for cardiovascular prevention in type 2 diabetes. PICO summary and expert commentary.
A small double-blind randomized trial found once-daily oral semaglutide 50 mg lowered ad libitum energy intake and body weight versus placebo over 20 weeks, with no delayed gastric emptying. PICO summary and expert commentary.
PIONEER 12 was a 26-week, double-blind, manufacturer-sponsored Phase IIIa trial showing oral semaglutide lowered HbA1c and body weight more than sitagliptin in a predominantly Chinese population with type 2 diabetes. PICO summary and expert commentary.
PIONEER 11, a 26-week Phase IIIa trial, found oral semaglutide monotherapy lowered HbA1c across all doses and reduced body weight at 7 mg and 14 mg versus placebo in a predominantly Chinese type 2 diabetes population. PICO summary and expert commentary.
STEP 10 randomised phase 3 trial of once-weekly semaglutide 2.4 mg versus placebo in adults with obesity and prediabetes: greater weight loss and reversion to normoglycaemia at 52 weeks. PICO summary and expert commentary.
A 12-week pilot randomised trial in 30 adults with type 2 diabetes compared a very-low calorie diet, semaglutide, and their combination on weight, body composition, and beta-cell function. PICO summary and expert commentary.
Semaglutide 2.4 mg weekly was superior to placebo for physical functioning across the four 68-week STEP 1-4 trials. PICO summary and expert commentary.
A prespecified analysis of the SELECT trial reports semaglutide produced a mean weight reduction of 10.2 percent versus 1.5 percent for placebo, sustained over four years in adults with cardiovascular disease and obesity but without diabetes. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
